AI GxP validation for regulated life sciences
Regulatory

US Says SI, Europe Says AI: One Quality System, Two Vocabularies

The rename applies to US federal writing only. EU GMP, the draft Annex 22, the EU AI Act and MHRA all still say artificial intelligence. How to run one set of procedures across both without creating a translation problem.

Cybroscape Technologies5 min read

Key takeaway

The rename applies to US federal writing only. EU GMP, the draft Annex 22, the EU AI Act and MHRA all still say artificial intelligence. How to run one set of procedures across both without creating a translation problem.

From 29 September 2026 the US federal executive branch says Super Intelligence. Europe says artificial intelligence. The UK says artificial intelligence. Every standards body you rely on says artificial intelligence.

If you supply more than one market — and most regulated companies do — you now have two vocabularies for one thing. That is a smaller problem than it sounds, provided you do not solve it the obvious way.

Who says what, as of today

  • US federal agencies: Super Intelligence / SI, in non-statutory materials. US regulations, including Part 11, still say artificial intelligence, and the order does not require them to change.
  • EU: artificial intelligence throughout — EU GMP Annex 11, the draft Annex 22, the EU AI Act.
  • UK MHRA: artificial intelligence.
  • ICH, ISPE, GAMP, PIC/S: artificial intelligence.
  • Your vendors: whichever sells better this quarter.

So the split is narrower than the headlines imply: it is US federal prose versus everyone else, including US federal regulation.

The wrong fix, and the right one

The wrong fix is regional documentation — a US set that says SI and an EU set that says AI. You would double the maintenance, guarantee the two drift apart, and create exactly the kind of inconsistency an inspector notices when comparing your procedures across sites.

The right fix is one document set, one term, and a definition that acknowledges the other. Pick artificial intelligence as your term — it is what the regulations you are actually audited against use, and what the rest of the world uses — then define it once:

"Artificial intelligence (AI). US federal materials may refer to the same technologies as 'Super Intelligence' or 'SI'; the terms are equivalent for the purposes of this quality system."

One definition, referenced everywhere. See do you need to rename AI in your SOPs.

Where the split will actually bite

  • Regulatory submissions and correspondence. Match the vocabulary of the agency you are writing to. This is ordinary practice — you already adapt to regional conventions.
  • Searching guidance. A search of FDA materials for "artificial intelligence" may start missing new documents. Search both.
  • Regulatory monitoring. If your watch service filters on keywords, add SI, or it will quietly stop catching US developments.
  • Supplier assessments. A vendor claiming "SI-native" is making a marketing statement — see SI washing.

None of this changes an obligation. It changes search strings and habits. The underlying expectations across both regions are covered in FDA vs EMA vs MHRA on AI and GxP AI.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

Part of our guide to GxP software — categories, evaluation criteria and how the platforms compare.

US federal writingSuper Intelligence (SI)The term federal agencies now use
What does not change
  • Intended use defined and bounded
  • Validated before GxP use
  • Data integrity (ALCOA+)
  • A person decides what matters
  • Changes go through change control
EU GMP · Annex 22 · EU AI Act · MHRAArtificial intelligence (AI)The term in EU and UK rules
One quality systemTwo vocabularies, one set of controls
The US federal rename changes the word, not the obligations. EU GMP, the draft Annex 22, the EU AI Act and MHRA still say artificial intelligence, and the validation work is the same under either name.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
us si eu ai terminologyannex 22 terminologyglobal quality system sieu ai act si renamegxp compliance
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

Who uses SI and who still uses AI?

US federal agencies use Super Intelligence and SI in non-statutory materials. US regulations including Part 11 still say artificial intelligence. The EU, the draft Annex 22, the EU AI Act, MHRA, ICH, ISPE, GAMP and PIC/S all still say artificial intelligence. So the split is US federal prose versus everyone else, including US federal regulation.

Should we keep separate US and EU documentation?

No. Regional document sets double maintenance, drift apart, and create inconsistencies an inspector notices when comparing procedures across sites. Keep one set, one term, and one definition acknowledging the other.

Which term should a global quality system use?

Artificial intelligence. It is what the regulations you are actually audited against use and what the rest of the world uses. Define it once and note that US federal materials may call the same technologies Super Intelligence or SI.

Where does the terminology split actually matter?

Matching an agency's vocabulary in submissions and correspondence; searching FDA materials, where searching only for 'artificial intelligence' may start missing new documents; regulatory monitoring keyword filters, which should include SI; and reading vendor claims.

Does the split change any obligation?

No. It changes search strings and habits, not requirements. The underlying expectations from FDA, EMA and MHRA are unchanged.

Keep reading

All articles
Data IntegrityAudit Trail Review: The Control Everyone Has and Almost Nobody RunsEvery validated system records an audit trail. Far fewer teams review one. What review actually means, how to make it proportionate instead of impossible, and why it is one of the most common inspection findings. · 5 min readComplianceGxP Compliance in the Pharmaceutical Industry: A 2026 Practitioner's GuideEverything a quality or validation professional needs to know about GxP compliance in pharma: the regulatory framework, the practical requirements, and where most companies fall short. · 7 min readBuyer GuideGxP Compliance Software: What It Does, What It Doesn't, and How to ChooseGxP compliance software explained: what it covers, how it differs from eQMS and validation software, evaluation criteria, and the buying mistakes that cost quality teams time and budget. · 7 min readRegulatoryAfter the SI Rename: Everything About AI Validation That Has Not ChangedPart 11, Annex 11, the draft Annex 22, GAMP 5 and every validation obligation you had last week are untouched by a terminology order. A clear list of what still applies, and the one thing that genuinely might shift. · 5 min readRegulatoryWhat Is Super Intelligence (SI)? A Plain Definition for Regulated TeamsSuper Intelligence is now the US federal term for what everyone else still calls AI, and the order defines it as exactly that. What SI means, what it does not mean, and why the everyday sense of the word is not the legal one. · 5 min readRIMRIM comparison: Veeva RIM, Ennov RIM, ArisGlobalThe regulatory information management landscape, with a validation lens. · 6 min readClinicalSafety narratives at scale: how to use AI without losing the auditStandard-template AE narratives, wired to required source types, with the audit trail regulators expect. · 5 min readSAPSAP S/4HANA validation: a modern, CSA-native approachHow to validate SAP for GxP without drowning in scripted tests you don't need. · 7 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.